Venture Investors was impressed with Inviragen ™s vision of building an international vaccine development company and the experience and complementary skills of their management team, said Mr. John Neis of Venture Investors. The Series A equity financing will fund the Phase 1 and 2 clinical testing of Inviragen ™s lead vaccines and fund company operations well into 2012.

Dr. Duane Gubler, Director of the Duke/National University of Singapore Program in Emerging Infectious Diseases and a founding advisor to Inviragen, stated, Inviragen and SingVax are technical innovators in vaccine development. We look forward to productive collaborations to study dengue, HFMD, Japanese encephalitis, chikungunya and other emerging infectious diseases.

Singapore is an ideal geographical base for Inviragen ™s vaccine development efforts, noted Dr. Joseph Santangelo, Chief Operating Officer. We have easy access to the growing economies and manufacturing capabilities of greater Asia, and we have access to world-class infectious disease and biotechnology research in Singapore.

We believe we are investing in a portfolio of vaccines that has the potential to make significant contributions to global public health, commented Mr. Alex Koo, Director, Phillip Private Equity. We also believe in the impressive and experienced team led by Dr. Stinchcomb and Dr. Santangelo.

Ms. Chu Swee Yeok, Chief Executive Officer, Bio*One Capital of EDB Investments commented, We are excited about Inviragen ™s efforts and progress in addressing important diseases not only prevalent in Singapore and Asia but increasingly prevalent in countries globally. Inviragen ™s integrated international R&D capabilities through operations in the United States and Singapore will position it well to drive the successful clinical and commercial development of these needed vaccines.

inviragen/